XenoPort, Inc. (Nasdaq: XNPT) today announced the initial public offering of 5,000,000 shares of its common stock at $10.50 per share. Shares of XenoPort’s common stock will be traded on the Nasdaq National Market under the trading symbol “XNPT”. XenoPort has granted the underwriters a 30-day option to purchase up to 750,000 additional shares of common stock at the initial public offering price, less the underwriting discounts and commissions, to cover over-allotments, if any. All of the shares are being offered by XenoPort.
Morgan Stanley & Co. Incorporated is acting as the sole book running and joint lead manager for the offering. Deutsche Bank Securities is acting as co-lead manager for the offering. Co-managers for the offering are Pacific Growth Equities, LLC and Lazard Capital Markets.
INFO SOURCES
XenoPort, Inc. (Nasdaq: XNPT)
3410 Central Expressway
Santa Clara, CA 95051
Phone: (408) 616-7200
Fax: (408) 616-7210
info@xenoport.com
FIRMS
XenoPort, Inc. is a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates that utilize the body's natural nutrient transporter mechanisms to improve the therapeutic benefits of existing drugs. Our most advanced product candidate is currently being evaluated in a Phase 2b clinical trial for the treatment of restless legs syndrome and has successfully completed a Phase 2a clinical trial for the management of post-herpetic neuralgia.
LINKED TO
Since its inception in 1999, XenoPort has raised over $90 million in private venture funding. XenoPort's investors include Alejandro Zaffaroni, Arch Ventures, CMEA Ventures, Frazier & Co., HBM BioVentures AG, Lilly BioVentures, Lombard Odier & Cie, Lotus BioScience Ventures, Novartis BioVentures Ltd., Orbimed Advisors, Skyline Ventures, The Invus Group, and Venrock Associates.
Supporting Material
